Yuankai Shi

Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs

SCHOLARLY PAPERS

14

DOWNLOADS

851

TOTAL CITATIONS

5

Scholarly Papers (14)

1.

Furmonertinib (AST2818) Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multi-Center, Double-Blind, Randomized Phase 3 Study (FURLONG)

Number of pages: 53 Posted: 10 Jan 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University - Department of Medical Oncology, Xuzhou Central Hospital - Department of Medical Oncology, China Medical University - Department of Medical Oncology, Central South University - Thoracic Medicine Department II, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Medical Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Xuzhou Medical College - Department of Respiratory Medicine, Nantong Tumor Hospital - Department of Medical Oncology, Wenzhou Medical University - Department of Pulmonary and Critical Care Medicine, Dalian University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Respiratory Medicine, Jilin Cancer Hospital - Department of Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Capital Medical University - Department of Oncology, Hebei University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Nantong University - Department of Respiratory Medicine, Shanghai Allist Pharmaceutical Technology, Shanghai Allist Pharmaceutical Technology and Shanghai Allist Pharmaceutical Technology
Downloads 214 (298,206)

Abstract:

Loading...

Furmonertinib, AST2818, NSCLC, EGFR, TKI

2.

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Number of pages: 31 Posted: 25 Sep 2018
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Shanghai Jiao Tong University (SJTU), Jilin Cancer Hospital, Tongji University - Department of Medical Oncology, Chinese Academy of Sciences (CAS), The Chinese University of Hong Kong (CUHK), Sun Yat-sen University (SYSU), Guangdong Academy of Medical Sciences, Central South University - Hunan Cancer Hospital, Nanjing Medical University - Jiangsu Institute of Cancer Research, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Leningrad Regional Clinical Hospital, Zhejiang University, Zhengzhou University - Henan Cancer Hospital, Sichuan University - West China Hospital, Central South University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Bristol Myers Squibb, Bristol Myers Squibb and Fudan University
Downloads 169 (369,910)
Citation 4

Abstract:

Loading...

nivolumab; PD-1 inhibitor; non-small-cell lung cancer; NSCLC; China; docetaxel; immunotherapy

3.

Efficacy and Safety of Sintilimab for Relapsed/Refractory Classic Hodgkin Lymphoma: A Multicentre, Single-Arm Phase II Study (ORIENT-1)

Number of pages: 118 Posted: 24 Sep 2018
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Experimental Hematology
Downloads 74 (668,486)

Abstract:

Loading...

PD-1, classic Hodgkin's Lymphoma, relapsed/refractory, ORIENT-1

4.

An Open-Label, Randomized Phase III Study of Telpegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer

Number of pages: 30 Posted: 12 Jun 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Henan University of Science and Technology - Department of Medical Oncology, Zhengzhou University - Affiliated Luoyang Central Hospital, Gannan Medical University - First Affiliated Hospital, Shaanxi Provincial Cancer Hospital, Hubei University of Arts and Science - Department of Oncology, Zhengzhou First People’s Hospital, Henan University of Science and Technology - Department of Medical Oncology, Luohe Central Hospital, Luohe Central Hospital, Harbin Medical University - Cancer Hospital, Xuzhou Medical University - Affiliated Hospital, Fujian Medical University - Zhangzhou Affiliated Hospital, Zhengzhou University - The Affiliated Cancer Hospital, Xinxiang Medical University - First Affiliated Hospital, The Second People’s Hospital of Lianyungang, The Second People’s Hospital of Lianyungang, Lianyungang First People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs and Xiamen Amoytop Biotech Co., LTD
Downloads 66 (710,163)

Abstract:

Loading...

Recombinant human granulocyte colony stimulating factor, filgrastim, pegfilgrastim, neutropenia, lung cancer, NSCLC

5.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study

Number of pages: 33 Posted: 22 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Guangdong Pharmaceutical University - Department of Medical Oncology, Sichuan University - Collaborative Innovation Center for Biotherapy, Guangxi Medical University - Department of Respiratory Oncology, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Fujian Medical University - Department of Radiation Oncology, Fujian Medical University - Department of Radiation Oncology, Yue Bei People's Hospital - Department of Oncology Radiotherapy, Zhejiang University - Department of Medical Oncology, Nantong Tumor Hospital - Department of Oncology Radiotherapy, Chongqing Medical University - First Affiliated Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Head and neck surgery, Guangzhou University of Chinese Medicine - Department of Oncology, Fujian Medical University - Department of Radiation Oncology, Zhengzhou University - Henan Cancer Hospital, Liuzhou Worker’s Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Anhui Provincial Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Guangdong Medical University - Department of Oncology, Fudan University - Internal Medicine Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University - Department of Medical Oncology, Huazhong University of Science and Technology - Department of Oncology, Hebei Medical University - Fourth Hospital, Harbin Medical University - Department of Medical Breast oncology, Nanjing Medical University - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Department of Radiation Oncology, Guizhou Medical University (Guiyang Medical University) - Department of Head and Neck oncology, Haikou People’s Hospital - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Tianjin Medical University - Department of Oncology Radiotherapy, Jilin University (JLU) - Cancer Center, Huazhong University of Science and Technology - Cancer Center, Wenzhou Medical University - Department of Medical Oncology, Yunnan Cancer Hospital, Central South University - Department of Oncology, Central South University - Department of Oncology, Shandong University - Department of Head and Neck neoplasm, Dalian University - Department of Oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Downloads 52 (797,164)

Abstract:

Loading...

KL-A167, nasopharyngeal carcinoma, efficacy, safety, PD-L1, biomarker

6.

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer

Number of pages: 42 Posted: 01 Jun 2021
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Chinese Academy of Medical Sciences - State Key Lab of Molecular Oncology, Geneplus-Beijing Co. Ltd. - Medical Center, Geneplus-Beijing Co. Ltd. - Medical Center, Capital Medical University - Department of Respiratory and Critical Care Medicine, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Geneplus-Beijing Co. Ltd., Geneplus-Beijing Institute, Geneplus-Beijing Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 39 (900,903)

Abstract:

Loading...

Small-cell lung cancer; Molecular tumor burden index; Circulating tumor DNA sequencing; Progression-free survival; Predictive classifiers

7.

The Changing Landscape of Anti-Lymphoma Drug Clinical Trials in Mainland China in the Past 15 Years (2005-2020): A Systematic Review

Number of pages: 21 Posted: 30 Oct 2020
Haizhu Chen, Yu Zhou, Xiaohong Han and Yuankai Shi
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chinese Academy of Medical Sciences - National Cancer Center and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 37 (919,262)
Citation 1

Abstract:

Loading...

Lymphoma, Clinical trials, Anti-cancer drug, China

8.

Artificial Neural Network Systems to Predict the Response to Sintilimab in Squamous-Cell Non-Small-Cell Lung Cancer Based on Data of Orient-3 Study

Number of pages: 39 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 35 (938,216)

Abstract:

Loading...

Squamous-cell non-small-cell lung cancer, Artificial neural network, Sintilimab, Response

9.

Effect of Surgical Resection on Survival in TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Number of pages: 17 Posted: 20 Dec 2019
Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences - Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Chinese Academy of Medical Sciences - Peking Union Medical College, Burning Rock Biotech, Geneplus-Beijing Institute, Geneplus-Beijing Institute, Chinese Academy of Medical Sciences - Peking Union Medical College and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 33 (958,057)

Abstract:

Loading...

10.

Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T-Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)

Number of pages: 28 Posted: 13 Oct 2020
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Jiangsu Cancer Hospital - Department of Oncology, Linyi Cancer Hospital - Department of Oncology, Huazhong University of Science and Technology - Department of Lymphoma, Capital Medical University - Department of Hematology, Zhengzhou University - Department of Oncology, Guangxi Medical University - Department of Hematology, Lymphoma and Pediatric Oncology, Guangxi Medical University - Department of Oncology, Henan Cancer Hospital - Department of Hematology, Jiangsu Province Hospital - Department of Hematology, Shanghai Oriental Hospital - Department of Oncology, Sun Yat-Sen University (SYSU) - Department of Hematology, Gansu Provincial Cancer Hospital - Department of Hematology, Hebei Medical University - Department of Hematology, Zhejiang Cancer Hospital - Department of Lymphoma, Sun Yat-Sen University (SYSU) - Department of Oncology, Hainan General Hospital - Department of Oncology, Shanxi Medical University - Department of Hematology, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Sichuan University - Department of Hematology, Sichuan University - Department of Oncology, Hunan Cancer Hospital - Department of lymphoma,, Jiangxi Cancer Hospital - Department of Oncology, The Fifth Medical Center of The General Hospital of The People's Liberation Army - Department of Lymphoma, Peking University - Department of Hematology, Guangzhou Medical University - Department of Oncology, Guangdong Academy of Medical Sciences - Department of Hematology, Government of the People's Republic of China - Tangdu Hospital - Department of Hematology, Lanzhou University - Department of Hematology, Southeast University - Department of Hematology, Nanfang Hospital - Department of Hematology, Dalian University - Department of Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Genor Biopharma Co., Ltd. - Department of Medical Science and Genor Biopharma Co., Ltd. - Department of Medical Science
Downloads 32 (968,087)

Abstract:

Loading...

peripheral T-cell lymphoma, PD-1 inhibitor, immunotherapy

11.

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of LY01610 (an Irinotecan Hydrochloride Liposome Injection) as a Second-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC)

Number of pages: 49 Posted: 19 Mar 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Government of the People's Republic of China - Second People's Hospital of Yibin, Bengbu Medical College - Department of Medical Oncology, Xuzhou Central Hospital - Department of Medical Oncology, Bengbu Medical College - Department of Medical Oncology, Guangdong Pharmaceutical University - Department of Medical Oncology, Shantou University - Medical College, Guangzhou Medical University, Xingtai People's Hospital, Chongqing Medical University, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, University of Science and Technology of China (USTC), Chongqing University, Chongqing University, Chongqing University, Luye Life Sciences Group, Nanjing Luye Pharmaceutical Co Ltd and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 31 (978,351)

Abstract:

Loading...

irinotecan liposome, LY01610, relapsed small cell lung cancer

12.

Rezivertinib Versus Gefitinib as First-Line Therapy for EGFR-Mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-Blinded, Randomized Phase 3 Study

Number of pages: 26 Posted: 13 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Henan University of Science and Technology - Department of Medical Oncology, Zhengzhou University - Department of Oncology, Central South University - Thoracic Medicine Department II, People's Hospital of Deyang City, Shanxi Medical University - First Hospital, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Sichuan Cancer Hospital - Department of Medical Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Sichuan University - Department of Respiratory and Critical Care Medicine, Guangxi Medical University, Shandong First Medical University - Department of Oncology, Qingdao University - Yantai Yuhuangding Hospital, Fujian Medical University - Fujian Cancer Hospital, Shantou University - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Army Medical University - Institute of Cancer, Xingtai Medical College - Cancer Center, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Gannan Medical University - First Affiliated Hospital, Central South University - Department of Respiratory Medicine, University of South China, Central South University, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Xinjiang Medical University - Pulmonary Cancer Medicine, Hubei University of Arts and Science - Department of Oncology, Xinjiang Medical University, Zhengzhou University - Henan Provincial People's Hospital, Qingdao University - Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Jilin University (JLU) - Cancer Center, Peking University - Department of Thoracic Medical Oncology, Cangzhou Central Hospital, Xi'an Jiaotong University (XJTU), China Medical University - Liaoning Cancer Hospital & Institute, Xiangtan Central Hospital, Nankai University - Tianjin Chest Hospital, Nanjing Medical University - Department of Oncology, Xiamen University, Huazhong University of Science and Technology - Department of Medical Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Henan University - Department of Oncology, Ningbo No. 2 Hospital, Zhengzhou University - Department of Medical Oncology, Shijiazhuang People’s Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Chifeng Municipal Hospital, Handan Central Hospital - Department of Oncology, Tianjin Medical University - The Second Hospital of Tianjin Medical University, Government of the People's Republic of China - Army Medical University, Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 29 (999,816)

Abstract:

Loading...

rezivertinib, gefitinib, NSCLC, EGFR TKI.

13.

Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials

Number of pages: 33 Posted: 20 Mar 2023
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - First Hospital, Shanxi Medical University - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Harbin Medical University - Department of Medical Oncology, Army Medical University - Institute of Cancer, Zhengzhou University - Department of Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Peking University - Department of Thoracic Medical Oncology, Qingdao University - Yantai Yuhuangding Hospital, Zhejiang University - The First Affiliated Hospital, Central South University - Thoracic Medicine Department II, Bengbu Medical College - First Affiliated Hospital, Sichuan University - Department of Thoracic Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Shandong First Medical University - Department of Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Chongqing University Cancer Hospital, Soochow University - Department of Pulmonary and Critical Care Medicine, Xingtai Medical College - Cancer Center, Nanjing Medical University - Department of Oncology, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Huazhong University of Science and Technology - Tongji Medical College, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Xuzhou Medical University - Department of Radiotherapy, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Anhui Medical University - Department of Oncology, Soochow University - Second Affiliated Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 27 (1,021,903)

Abstract:

Loading...

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC

14.

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb Study

Number of pages: 254 Posted: 11 May 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - Department of Medical Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Central South University - Thoracic Medicine Department II, Sichuan University - Department of Thoracic Oncology, Zhengzhou University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Army Medical University - Institute of Cancer, Harbin Medical University - Department of Respiratory Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Shandong First Medical University - Department of Oncology, Peking University - Department of Thoracic Medical Oncology, Xingtai Medical College - Cancer Center, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Zhengzhou University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Chongqing University Cancer Hospital - Department of Palliative Care, Xuzhou Medical University - Department of Radiotherapy, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Key Laboratory of Respiratory Disease of Zhejiang Province, Shantou University - Department of Medical Oncology, Nanjing Medical University - Department of Oncology, Anhui Medical University - Department of Oncology, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 13 (1,195,449)

Abstract:

Loading...

Rezivertinib, BPI-7711, NSCLC, EGFR T790M mutation, Third-generation EGFR TKI